Systematic Financial Management LP cut its holdings in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 5.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,655 shares of the biopharmaceutical company’s stock after selling 3,320 shares during the quarter. Systematic Financial Management LP’s holdings in Horizon Therapeutics were worth $1,524,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Calamos Advisors LLC grew its position in Horizon Therapeutics by 3.1% during the 1st quarter. Calamos Advisors LLC now owns 13,400 shares of the biopharmaceutical company’s stock worth $354,000 after purchasing an additional 400 shares during the last quarter. Creative Planning grew its position in Horizon Therapeutics by 3.2% during the 1st quarter. Creative Planning now owns 16,290 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 500 shares during the last quarter. D.A. Davidson & CO. lifted its stake in shares of Horizon Therapeutics by 5.1% in the 4th quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 512 shares during the period. American International Group Inc. lifted its stake in shares of Horizon Therapeutics by 0.8% in the 4th quarter. American International Group Inc. now owns 110,573 shares of the biopharmaceutical company’s stock worth $2,161,000 after acquiring an additional 868 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Horizon Therapeutics in the 1st quarter worth $29,000. 83.32% of the stock is currently owned by institutional investors.

Shares of NASDAQ HZNP opened at $26.95 on Thursday. The company has a current ratio of 1.74, a quick ratio of 1.97 and a debt-to-equity ratio of 0.90. Horizon Therapeutics PLC has a 52 week low of $14.82 and a 52 week high of $29.44.

Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.20. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The firm had revenue of $280.00 million during the quarter, compared to analysts’ expectations of $238.35 million. During the same quarter last year, the business earned $0.03 earnings per share. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. On average, sell-side analysts predict that Horizon Therapeutics PLC will post 1.64 EPS for the current year.

In related news, EVP Geoffrey M. Curtis sold 10,080 shares of the firm’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $21.21, for a total value of $213,796.80. Following the completion of the sale, the executive vice president now owns 35,367 shares in the company, valued at $750,134.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is owned by company insiders.

Several analysts have recently commented on HZNP shares. Cantor Fitzgerald raised their target price on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. BidaskClub cut shares of Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 20th. Jefferies Financial Group raised their target price on shares of Horizon Therapeutics to $34.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Cowen set a $33.00 target price on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, February 28th. Finally, Piper Jaffray Companies set a $33.00 target price on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 4th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $30.83.

WARNING: “Systematic Financial Management LP Trims Holdings in Horizon Therapeutics PLC (HZNP)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2019/05/16/systematic-financial-management-lp-trims-holdings-in-horizon-therapeutics-plc-hznp.html.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: What is a Call Option?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.